Bristol-Myers Squibb Co (NYSE:BMY) – Stock analysts at Jefferies Group lifted their FY2017 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a research report issued to clients and investors on Tuesday. Jefferies Group analyst J. Holford now expects that the biopharmaceutical company will post earnings of $2.99 per share for the year, up from their previous forecast of $2.98. Jefferies Group has a “Hold” rating and a $72.00 price objective on the stock. Jefferies Group also issued estimates for Bristol-Myers Squibb’s FY2021 earnings at $4.99 EPS.

BMY has been the subject of several other research reports. UBS Group restated a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price target for the company in a research note on Monday, October 9th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Finally, Citigroup raised their price target on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $65.11.

Shares of Bristol-Myers Squibb (NYSE:BMY) opened at $61.83 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb has a one year low of $46.01 and a one year high of $66.10. The stock has a market cap of $101,200.00, a P/E ratio of 24.34, a PEG ratio of 2.20 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter in the previous year, the business earned $0.77 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Hawaiian Bank lifted its holdings in shares of Bristol-Myers Squibb by 5.5% during the 2nd quarter. First Hawaiian Bank now owns 6,283 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 330 shares during the last quarter. Perkins Coie Trust Co lifted its holdings in shares of Bristol-Myers Squibb by 33.6% during the 2nd quarter. Perkins Coie Trust Co now owns 3,084 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 775 shares during the last quarter. City Holding Co. lifted its holdings in shares of Bristol-Myers Squibb by 23.6% during the 2nd quarter. City Holding Co. now owns 40,390 shares of the biopharmaceutical company’s stock worth $2,251,000 after acquiring an additional 7,705 shares during the last quarter. Koshinski Asset Management Inc. lifted its holdings in shares of Bristol-Myers Squibb by 46.6% during the 2nd quarter. Koshinski Asset Management Inc. now owns 8,869 shares of the biopharmaceutical company’s stock worth $494,000 after acquiring an additional 2,820 shares during the last quarter. Finally, Dynamic Advisors Solutions LLC lifted its holdings in shares of Bristol-Myers Squibb by 126.3% during the 2nd quarter. Dynamic Advisors Solutions LLC now owns 17,365 shares of the biopharmaceutical company’s stock worth $968,000 after acquiring an additional 9,690 shares during the last quarter. Hedge funds and other institutional investors own 69.74% of the company’s stock.

In related news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.59%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is currently 62.99%.

TRADEMARK VIOLATION NOTICE: “FY2017 Earnings Estimate for Bristol-Myers Squibb Co (BMY) Issued By Jefferies Group” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/fy2017-earnings-estimate-for-bristol-myers-squibb-co-bmy-issued-by-jefferies-group/1813129.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Earnings History and Estimates for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.